Clinical chemistry- liver function (hepatitis)

rubenstein

HAV

Short incubation (2-6wks), most common, RNA, Fecal-oral route

HAV symptoms

Self-limiting, no chronic state

HAV Ag

shed in feces during incubation period/ early stages of infection

HEP A- IgM Ab

detectable after onset of clinical illness, declines until no longer detectable

HAV IgG Ab

detectable soon after anti-HAV IgM manifests, persist for years after infection, lifelong immunity

Anti-HAV IgM

present in pts with symptoms- acute HAV

Anti-HAV IgG

previous infection/immunity, protects against subsequent infections

HAV prevention

vaccine

HBV

long incubation hepatitis

HBV route of transmission

needles, sex

HBV incubation period

8-26 wks

HBsAg

protein on surface of virus, 1st sign infection, detectable 2 wks after infection, Indicated active HBV infection

anti-HBs

produced in response to HBsAg, means recovery from infection and is immune or had the vaccine

HBeAg

from actively replicating HEP B infection, active infection and ability to spread to others

anti-HBe

in response to envelope Ag, recovery from HBV

HBcAg

present in nuclei of infected liver cells, not detectable in blood

anti-HBc, total

total of both IgM/IgG Ab, in response to HEP B core antigen, current or past infection, persists for life

anti-HBc, IgM

in response to HBcAg, current or recent acute infection

Hep B viral DNA (HBV DNA)

detects viral genetic material, active HBV infection

HEP C

most common chronic blood borne infection in the world

HCV transmission

percutaneous- needles

HCV incubation

2-15wks

HCV virus

RNA, acute/chronic states

ANti-HCV Ab

not always detectable early, almost always in later stages, current or past infection

HCV RNA

current Hep C infection

HCV prevention

no vaccine

HDV

delta hepatitis, needles and sex, 2-8weeks

HDV virus

circular RNA , hepatitis delta antigen, viral envelope containing HBsAg

HDV causes

disease in pts who currently infected with HBV- requires confection to replicate

anti-HDV, IgM

days to weeks after onset, acute-infection

Anti-HDV, IgG

recovery from HDV

HDV RNA

active viral replication, active infection

HDV prevention

no vaccine, prevent HBV

HEV route transmission

fecal-oral

HEV incubation

3-6

HEV virus

non enveloped, single stranded RNA, common acute state

HEV acute infection

self-limiting, looks like HAV- more sever in pregnant individuals

anti-HEV, IgM

acute infection

IgG anti HEV

current/past infection

HEV RNA

current hep E infection

HEV prevention

no vaccine